Target intelligence / Profile preview

Renal dehydropeptidase I (Dipeptidase 1) (DHP-I)

Target
DHP-I
Molecular classification
Enzyme, Dipeptidase, Metalloprotease, Hydrolase
01

Overview

Renal dehydropeptidase I (DHP-I), also known as Dipeptidase 1 (DPEP1), is a zinc-dependent metalloenzyme primarily located on the brush border membrane of the renal proximal tubules (UniProt: P16444). Its physiological role involves the hydrolysis of various dipeptides and the conversion of leukotriene D4 into leukotriene E4. In clinical pharmacology, DHP-I is a significant therapeutic target because it rapidly degrades carbapenem antibiotics, such as imipenem, into inactive and potentially nephrotoxic metabolites (PubMed: 32899204). To ensure the efficacy and safety of these antibiotics, DHP-I inhibitors like cilastatin are co-administered, which prevents renal degradation and extends the half-life of the drug (NIH: PubChem). Although the user referred to it as "Bacterial dehydropeptidase I," the enzyme is actually a human host protein; bacterial resistance to carbapenems is typically mediated by distinct enzymes known as carbapenemases, though some bacterial metallo-beta-lactamases (e.g., CphA) share structural similarities and can also be inhibited by cilastatin (Antimicrob Agents Chemother. 1995; 39: 1629-1631).

Other names
Dehydropeptidase IDHP-IDipeptidase 1DPEP1Renal dipeptidaseMicrosomal dipeptidaseMembrane dipeptidase
02

Mechanism of action

Inhibition of renal dehydropeptidase I prevents the hydrolysis of carbapenem antibiotics in the kidneys, thereby maintaining therapeutic systemic levels and preventing the formation of nephrotoxic metabolites.

03

Biological functions

Hydrolysis of dipeptidesDegradation of carbapenem antibioticsMetabolism of leukotriene D4 to leukotriene E4
04

Disease associations

InfectionNephrotoxicity
05

Safety considerations

Potential for central nervous system toxicity (seizures) when co-administered with imipenemHypersensitivity reactionsRenal impairment considerations
06

Interacting drugs

Cilastatin

3 more in the full profile.

07

Biomarkers

Urinary imipenem levelsSerum creatinineBlood urea nitrogen (BUN)

Beyond the preview

Go deeper on Renal dehydropeptidase I (Dipeptidase 1) (DHP-I).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Renal dehydropeptidase I (Dipeptidase 1) (DHP-I).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call